Telomir Pharmaceuticals, Inc.

Stage 4 · Declining · week 20

As of Oct 22, 2026, Telomir Pharmaceuticals is in Stage 4, the downtrend phase, now in week 20 (since Jun 2, 2026). It closed at $1.01, 35.7% below its 52-week high and below its 200-day average, which is falling.

$1.01

+1.00% today

$74.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TELO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-02-09 → 2026-10-22

S? 41w

S4 38w

S4 18w

S4 20w

2024-02-092026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 9w → S1 4w → S4 38w → S1 3w → S4 18w → S1 6w → S4 20w current

Total tracked: 140 weeks across 8 stage runs.

TELO among Biotechnology292nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…292	TELOTelomir Pharmaceuticals, Inc.	Stage 4 · wk 20	32	−17.2%

vs 52W High

-35.7%

$0.92 lo$1.57 hi

35.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 20

1w13w26w

Week 20, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-18.2%

200 DMA: $1.23 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.01x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-17.2%

-12.2%

-26.8%

YTD

-24.6%

-32.7%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 20 · Vol 1.01x

2026-10-21S4

Wk 20 · Vol 0.40x

2026-10-20S4

Wk 20 · Vol 0.85x

2026-10-19S4

Wk 20 · Vol 0.32x

2026-10-16S4

Wk 20 · Vol 0.43x

2026-10-15S4

Wk 19 · Vol 0.76x

2026-10-14S4

Wk 19 · Vol 0.96x

2026-10-13S4

Wk 19 · Vol 0.59x

2026-10-12S4

Wk 19 · Vol 0.79x

2026-10-09S4

Wk 19 · Vol 0.72x

2026-10-08S4

Wk 18 · Vol 1.47x

2026-10-07S4

Wk 18 · Vol 1.39x

Moving averages & range

50 DMA

$1.14

200 DMA

$1.23

52W High

$1.57

52W Low

$0.92

5D Low

$1.00

Resistance levels (recent highs)

20d High

$1.23

60d High

$1.25

120d High

$1.42

250d High

$1.57

Next resistance

+21.8%

to 20d High

ROE

-213.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 13.8

Telomir Pharmaceuticals: quick answers

What stage is Telomir Pharmaceuticals in?

As of Oct 22, 2026, Telomir Pharmaceuticals (TELO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 2, 2026 and is in week 20. What the four stages mean

Is Telomir Pharmaceuticals in an uptrend?

No. Telomir Pharmaceuticals is in a Stage 4 downtrend. It trades 18.2% below its 200-day average, which is falling.

How far is Telomir Pharmaceuticals from its 52-week high?

Telomir Pharmaceuticals closed at $1.01 on Oct 22, 2026, 35.7% below its 52-week high of $1.57. Its 52-week low is $0.92.

How has Telomir Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Telomir Pharmaceuticals is down 32.7% over the past year and down 24.6% so far in 2026.

Which sector and industry is Telomir Pharmaceuticals in?

Telomir Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.